Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 20/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MT-CO1 | P00395 | 1/20 | 0.52 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5664167 | 0.83 | PTGS2 (0.57) | PTGS2PTGS1 | |
| SCHEMBL8087013 | 0.83 | PTGS2 (0.60) | PTGS2PTGS1 | |
| SCHEMBL23093213 | 0.82 | PTGS2 (0.47) | PTGS2PTGS1 | |
| SCHEMBL29802404 | 0.82 | PTGS2 (0.47) | PTGS2PTGS1 | |
| SCHEMBL6377935 | 0.80 | PTGS2 (0.55) | PTGS2PTGS1KDM4EMT-CO1MT-CO2 | |
| SCHEMBL6242607 | 0.80 | PTGS2 (0.60) | PTGS2PTGS1 | |
| SCHEMBL6377943 | 0.79 | PTGS2 (0.56) | PTGS2PTGS1KDM4EMT-CO1MT-CO2 | |
| SCHEMBL5084380 | 0.76 | PTGS2 (0.50) | PTGS2PTGS1KDM4EMT-CO1MT-CO2 | |
| SCHEMBL212410 | 0.76 | PTGS2 (0.51) | PTGS2PTGS1KDM4EMT-CO1MT-CO2 | |
| SCHEMBL8483933 | 0.75 | PTGS2 (0.78) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135506-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders | PHARMACIA CORPORATION | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135506-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885KDM4E 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.